Antigenic stimulation with cytochrome P450 2J expressed in mouse hepatocellular carcinoma cells regulates host anti-tumour immunity

Clinical and Experimental Immunology

Volumn 156, Issue 2, 2009, Pages 344-352

  Homma, S ^a,b   Koido, S ^a   Sagawa, Y ^b   Suzuki, H ^a   Komita, H ^a   Nagasaki, E ^a,b   Takahara, A ^a,b   Horiguchi Yamada, J ^b   Tajiri, H ^a   Zeldin, D C ^d   Obata, T ^c  

^a JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Department of Oncology ^*  (Japan)

^c Institute of DNA Medicine   (Japan)

^d NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

Author keywords

Dendritic cell; Immune regulation; Liver cancer; MHC class II; Treg

Indexed keywords

AMINO ACID; BINDING PROTEIN; CD11 ANTIGEN; CD4 ANTIGEN; CYTOCHROME P450; CYTOCHROME P450 2J; GAMMA INTERFERON; ISOENZYME; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; TRANSCRIPTION FACTOR FOXP3; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGENICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLADDER TUMOR; CANCER GROWTH; CANCER IMMUNIZATION; CANCER INHIBITION; CARCINOMA CELL; CYTOKINE PRODUCTION; DENDRITIC CELL; HOST RESISTANCE; IMMUNOREGULATION; IMMUNOSTIMULATION; IN VIVO STUDY; LIVER CELL CARCINOMA; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN ISOLATION; REGULATORY T LYMPHOCYTE; SPLEEN CELL; SUPPRESSOR CELL; TANDEM MASS SPECTROMETRY; TUMOR CELL; TUMOR IMMUNITY; TUMOR REJECTION;

AMINO ACID SEQUENCE; ANIMALS; ANTIGENS, NEOPLASM; CANCER VACCINES; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CHROMATOGRAPHY, AFFINITY; CYTOCHROME P-450 ENZYME SYSTEM; DENDRITIC CELLS; DOSE-RESPONSE RELATIONSHIP, DRUG; HISTOCOMPATIBILITY ANTIGENS CLASS II; IMMUNE TOLERANCE; INTERFERON-GAMMA; LIVER NEOPLASMS, EXPERIMENTAL; MALE; MICE; MICE, INBRED C3H; MOLECULAR SEQUENCE DATA; PROTEIN ISOFORMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SPLEEN; TANDEM MASS SPECTROMETRY;

EID: 64649094830     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2009.03900.x     Document Type: Article

References (40)

1. Finn OJ. Cancer immunology. N Engl J Med 2008 358 : 2704 15.
2. Crosti M, Longhi R, Consogno G, Melloni G, Zannini P, Protti MP. Identification of novel subdominant epitopes on the carcinoembryonic antigen recognized by CD4+ T cells of lung cancer patients. J Immunol 2006 176 : 5093 9.
3. Guilloux Y, Viret C, Gervois N et al. Defective lymphokine production by most CD8+ and CD4+ tumor-specific T cell clones derived from human melanoma-infiltrating lymphocytes in response to autologous tumor cells in vitro. Eur J Immunol 1994 24 : 1966 73.
4. Anderson MJ, Shafer-Weaver K, Greenberg NM, Hurwitz AA. Tolerization of tumor-specific T cells despite efficient initial priming in a primary murine model of prostate cancer. J Immunol 2007 178 : 1268 76.
5. Zou W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer 2005 5 : 263 74.
6. Gabrilovich D. Mechanisms and functional significance of tumour-induced dendritic-cell defects. Nat Rev Immunol 2004 4 : 941 52.
7. Gajewski TF. Identifying and overcoming immune resistance mechanisms in the melanoma tumor microenvironment. Clin Cancer Res 2006 12 : 2326s 30s.
8. Redmond WL, Marincek BC, Sherman LA. Distinct requirements for deletion versus anergy during CD8 T cell peripheral tolerance in vivo. J Immunol 2005 174 : 2046 53.
9. Topalian SL. MHC class II restricted tumor antigens and the role of CD4+ T cells in cancer immunotherapy. Curr Opin Immunol 1994 6 : 741 5.
10. Wang RF. The role of MHC class II-restricted tumor antigens and CD4+ T cells in antitumor immunity. Trends Immunol 2001 22 : 269 76.
11. Toes RE, Ossendorp F, Offringa R, Melief CJ. CD4 T cells and their role in antitumor immune responses. J Exp Med 1999 189 : 753 6.
12. Guery JC, Adorini L. Selective immunosuppression of class II-restricted T cells by MHC class II-binding peptide. Crit Rev Immunol 1993 13 : 195 206.
13. Campi G, Crosti M, Consogno G et al. CD4(+) T cells from healthy subjects and colon cancer patients recognize a carcinoembryonic antigen-specific immunodominant epitope. Cancer Res 2003 63 : 8481 6.
14. Chahal FC, Entwistle J, Glover N, Macdonald GC. A targeted proteomic approach for the identification of tumor-associated membrane antigens using the ProteomeLab PF-2D in tandem with mass spectrometry. Biochem Biophys Res Commun 2006 348 : 1055 62.
15. Dengjel J, Nastke MD, Gouttefangeas C et al. Unexpected abundance of HLA class II presented peptides in primary renal cell carcinomas. Clin Cancer Res 2006 12 : 4163 70.
16. Zeng G, Aldridge ME, Tian X et al. Dendritic cell surface calreticulin is a receptor for NY-ESO-1: direct interactions between tumor-associated antigen and the innate immune system. J Immunol 2006 177 : 3582 9.
17. Rohn TA, Reitz A, Paschen A et al. A novel strategy for the discovery of MHC class II-restricted tumor antigens: identification of a melanotransferrin helper T-cell epitope. Cancer Res 2005 65 : 10068 78.
18. Irie M, Homma S, Komita H et al. Inhibition of spontaneous development of liver tumors by inoculation with dendritic cells loaded with hepatocellular carcinoma cells in C3H/HeNCRJ mice. Int J Cancer 2004 111 : 238 45.
19. Wu S, Moomaw CR, Tomer KB, Falck JR, Zeldin DC. Molecular cloning and expression of CYP2J2, a human cytochrome P450 arachidonic acid epoxygenase highly expressed in heart. J Biol Chem 1996 271 : 3460 8.
20. Ma J, Bradbury JA, King L et al. Molecular cloning and characterization of mouse CYP2J6, an unstable cytochrome P450 isoform. Biochem Pharmacol 2002 64 : 1447 60.
21. Iinuma T, Homma S, Noda T, Kufe D, Ohno T, Toda G. Prevention of gastrointestinal tumors based on adenomatous polyposis coli gene mutation by dendritic cell vaccine. J Clin Invest 2004 113 : 1307 17.
22. Qu W, Bradbury JA, Tsao CC et al. Cytochrome P450 CYP2J9, a new mouse arachidonic acid omega-1 hydroxylase predominantly expressed in brain. J Biol Chem 2001 276 : 25467 79.
23. Komita H, Homma S, Saotome H, Zeniya M, Ohno T, Toda G. Interferon-gamma produced by interleukin-12-activated tumor infiltrating CD8+T cells directly induces apoptosis of mouse hepatocellular carcinoma. J Hepatol 2006 45 : 662 72.
24. Green DR, Droin N, Pinkoski M. Activation-induced cell death in T cells. Immunol Rev 2003 193 : 70 81.
25. Sotomayor EM, Borrello I, Tubb E et al. Conversion of tumor-specific CD4+ T-cell tolerance to T-cell priming through in vivo ligation of CD40. Nat Med 1999 5 : 780 7.
26. Wing K, Ekmark A, Karlsson H, Rudin A, Suri-Payer E. Characterization of human CD25+ CD4+ T cells in thymus, cord and adult blood. Immunology 2002 106 : 190 9.
27. Sakaguchi S. The origin of FOXP3-expressing CD4+ regulatory T cells: thymus or periphery. J Clin Invest 2003 112 : 1310 2.
28. Shevach EM, McHugh RS, Piccirillo CA, Thornton AM. Control of T-cell activation by CD4+ CD25+ suppressor T cells. Immunol Rev 2001 182 : 58 67.
29. Shevach EM. Certified professionals: CD4(+)CD25(+) suppressor T cells. J Exp Med 2001 193 : F41 6.
30. von Herrath MG, Harrison LC. Antigen-induced regulatory T cells in autoimmunity. Nat Rev Immunol 2003 3 : 223 32.
31. Khong HT, Restifo NP. Natural selection of tumor variants in the generation of 'tumor escape' phenotypes. Nat Immunol 2002 3 : 999 1005.
32. Curiel TJ, Coukos G, Zou L et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004 10 : 942 9.
33. Nishikawa H, Kato T, Tanida K et al. CD4+ CD25+ T cells responding to serologically defined autoantigens suppress antitumor immune responses. Proc Natl Acad Sci USA 2003 100 : 10902 6.
34. Nishikawa H, Kato T, Tawara I et al. Accelerated chemically induced tumor development mediated by CD4+CD25+ regulatory T cells in wild-type hosts. Proc Natl Acad Sci USA 2005 102 : 9253 7.
35. Gabrilovich D, Ishida T, Oyama T et al. Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo. Blood 1998 92 : 4150 66.
36. Wang T, Niu G, Kortylewski M et al. Regulation of the innate and adaptive immune responses by stat-3 signaling in tumor cells. Nat Med 2004 10 : 48 54.
37. Marigo I, Dolcetti L, Serafini P, Zanovello P, Bronte V. Tumor-induced immune dysfunctions by myeloid derived suppressor cells. Immunol Rev 2008 222 : 162 79.
38. Rodriguez PC, Quiceno DG, Zabaleta J et al. Arginase I production in the tumor microenvironment by mature myeloid cells inhibits T-cell receptor expression and antigen-specific T-cell responses. Cancer Res 2004 64 : 5839 49.
39. Huang B, Pan PY, Li Q et al. Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. Cancer Res 2006 66 : 1123 31.
40. Ghiringhelli F, Puig PE, Roux S et al. Tumor cells convert immature myeloid dendritic cells into TGF-beta-secreting cells inducing CD4+CD25+ regulatory T cell proliferation. J Exp Med 2005 202 : 919 29.